Data gathered: November 23
AI Stock Analysis - Atricure (ATRC)
Analysis generated November 22, 2024. Powered by Chat GPT.
AtriCure is a leading medical device company specializing in treatments for atrial fibrillation and related conditions. The company focuses on developing innovative products and technologies for the treatment of cardiac arrhythmias and surgical ablation. Their portfolio includes proprietary devices and systems designed for both minimally invasive and open surgical procedures, positioning AtriCure as a prominent player in its field.
Stock Alerts - Atricure (ATRC)
 |
Atricure | November 12 Employee Rating is up by 2.2% over the last month. |
|
Atricure | November 6 Price is up by 5.2% in the last 24h. |
|
Atricure | November 5 Price is up by 5.7% in the last 24h. |
|
Atricure | October 30 Price is up by 17.1% in the last 24h. |
Alternative Data for Atricure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 50 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| Patents | 150 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 14 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,277 | Sign up | Sign up | Sign up |
| Instagram Followers | 759 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 384 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,596 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,100 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 91 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,245 | Sign up | Sign up | Sign up |
About Atricure
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.
| Price | $35.74 |
| Target Price | Sign up |
| Volume | 446,970 |
| Market Cap | $1.74B |
| Year Range | $19.86 - $38.2 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Medical & Dental Instruments |
In the news
 |
Assetmark Inc. Has $39,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)November 19 - ETF Daily News |
|
AtriCure (ATRC) – Research Analysts’ Recent Ratings ChangesNovember 18 - ETF Daily News |
 |
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These ResultsOctober 31 - Yahoo |
|
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Buy” by AnalystsOctober 31 - ETF Daily News |
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), 10x Genomics (TXG) and Chugai Pharmaceutical Co (OtherCHGCF)October 30 - TipRanks |
|
 |
AtriCure (NASDAQ:ATRC) Shares Gap Up After Earnings BeatOctober 30 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 116M | 29M | 87M | -7.9M | -5.3M | -0.170 |
| Q2 '24 | 116M | 29M | 87M | -8M | -7M | -0.170 |
| Q1 '24 | 109M | 28M | 81M | -13M | -9.3M | -0.280 |
| Q4 '23 | 107M | 27M | 80M | -9.8M | -5.7M | -0.210 |
| Q3 '23 | 98M | 24M | 74M | -9.1M | -5.3M | -0.200 |
Insider Transactions View All
| Yuen Maggie filed to sell 8,970 shares at $24.1. August 19 '24 |
| Privitera Salvatore filed to buy 103,290 shares at $22.3. May 31 '24 |
| Noznesky Justin J filed to sell 71,284 shares at $24.1. May 3 '24 |
| Noznesky Justin J filed to sell 72,784 shares at $30.4. April 3 '24 |
| Dahlquist Karl S. filed to sell 50,954 shares at $32.2. March 20 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Align TechnologyALGN |
$225.89 0% | 48 |
 |
DentsplyXRAY |
$18.77 0% | 46 |
 |
LeMaitre VascularLMAT |
$107.97 0% | 42 |
 |
iRhythm TechnologiesIRTC |
$73.99 0% | 41 |
 |
NovoCureNVCR |
$17.73 0% | 57 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
| Josh Gottheimer |
Jul 9, 24 | Sell | $1K - $15K |
Read more about Atricure (ATRC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Atricure?
The Market Cap of Atricure is $1.74B.
What is the current stock price of Atricure?
Currently, the price of one share of Atricure stock is $35.74.
How can I analyze the ATRC stock price chart for investment decisions?
The ATRC stock price chart above provides a comprehensive visual representation of Atricure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Atricure shares. Our platform offers an up-to-date ATRC stock price chart, along with technical data analysis and alternative data insights.
Does ATRC offer dividends to its shareholders?
As of our latest update, Atricure (ATRC) does not offer dividends to its shareholders. Investors interested in Atricure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Atricure?
Some of the similar stocks of Atricure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and NovoCure.
.